Objective: To assess the feasibility of synthesis of O-(2-[(18)F]-fluoroethyl)-l-tyrosine (FET), a new positron emission tomographic (PET) tracer described in several studies but not yet considered standard in management of glioma, in routine practice and to determine FET uptake in a homogeneous group of patients with suspected high-grade glioma.
Design: Prospective nonrandomized trial.
Patients: Twelve patients with suspicion of high-grade glioma.
Results: The mean (SD) FET uptake ratio was 3.15 (0.72) for the 12 patients and 3.16 (0.75) for the 11 patients with glioblastoma.
Conclusion: The initial results are promising and indicate that FET PET is a valuable and applicable tool for the imaging of high-grade glioma.